8-K
filed April 11, 2022, 7:59 PM ET
ticker MLTX
CIK 0001821586
M&A
confidence high
sentiment neutral
materiality 0.80
MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq
MoonLake Immunotherapeutics
- Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).
- Issued 36.9M Class A shares and 15.8M Class C shares; PIPE investors subscribed 11.7M Class A shares at $10.00 each, grossing ~$116M.
- Existing MoonLake AG shareholders received 18.5M Class A and 15.8M Class C shares; lock-up periods of 6 to 12 months apply.
- Helix contributed $134.6M to MoonLake AG, including $15M loan repayment to Cormorant Asset Management.
- New equity incentive plan adopted; initial grants of 45,000 options per non-management director; indemnification agreements executed.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Will Lewis resigned as Director at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Director
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Schmid resigned as Director at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Director
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Andrew J. Phillips resigned as Officer at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Officer
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Nancy Chang resigned as Director at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Director
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bihua Chen resigned as Officer at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Officer
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bihua Chen resigned as Director at MoonLake Immunotherapeutics.
- Action
- resigned
- Role
- Director
Exact text from the filing
In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.